Male Tumour Markers
Private Male Tumour Markers blood test in London for £299, assessing 5 cancer-associated biomarkers with laboratory results expected in around 1 day.
Turnaround time
1 business day
Biomarkers count
5
Book your test
Choose Service Type
Professional phlebotomist comes to you
+ £{{ home_visit_fee }}
Visit our clinic for your test
{{ clinic_visit_fee > 0 ? '+ £' + clinic_visit_fee : 'Free' }}
Home Visit Details
Home visits require at least 24 hours notice.
Select a clinic: Sorting by distance…
{{ clinicAddress(clinic) }}
{{ clinicAddress(selectedClinic) }}
Select a date
Select an hour
Available time slots: {{ timeSlots.length}}
Overview of the Male Tumour Markers Test
The Male Tumour Markers blood test measures 5 laboratory biomarkers that can be associated with particular cancers, organ systems or increased cell turnover.
The profile includes Carcino Embryonic Antigen, Alpha Fetoprotein, Cancer Antigen 19-9, Prostate Specific Antigen (Total) and Lactate Dehydrogenase.
Tumour markers require careful interpretation.
They are not equivalent to a cancer diagnosis, and most tumour markers are not suitable for diagnosing or excluding cancer when used alone.
A marker can be elevated for non-cancerous reasons.
Conversely, a person can have cancer while a tumour marker remains within the laboratory reference range.
The value of tumour-marker testing therefore depends heavily on why the test was requested.
These markers are often most useful when interpreted alongside symptoms, medical history, imaging, physical examination or previous results.
Prostate Specific Antigen (Total) is produced by prostate tissue.
PSA can rise with prostate cancer, but it can also increase with benign prostate enlargement, prostatitis, urinary infection, recent ejaculation and some prostate procedures.
Carcino Embryonic Antigen is commonly associated with monitoring colorectal cancer but can also be raised in other malignancies and in some benign conditions.
Smoking can influence CEA levels.
Alpha Fetoprotein can be relevant to hepatocellular carcinoma and selected germ-cell tumours, while liver disease can also alter AFP.
Cancer Antigen 19-9 is most commonly associated with pancreatic and biliary malignancies, but benign biliary obstruction and inflammation can also increase it.
Lactate Dehydrogenase is particularly non-specific.
LDH can rise whenever there is increased tissue injury or cell turnover, including liver, muscle, blood and other conditions.
The five markers therefore provide a broad laboratory panel but should never be treated as a definitive cancer-screening result.
What Does the Male Tumour Markers Test Check?
The profile measures five laboratory markers associated with prostate health, gastrointestinal and hepatobiliary conditions, selected germ-cell tumours and general tissue turnover. This test measures 5 specialist biomarkers.
Carcino Embryonic Antigen
Measures CEA, a tumour-associated marker commonly used in colorectal cancer monitoring that can also be elevated in other malignant and non-malignant conditions.
Alpha Fetoprotein
Measures AFP, a protein used in the assessment and monitoring of selected liver and germ-cell tumours while also recognising that non-malignant liver conditions can affect the result.
Cancer Antigen 19-9
Measures CA 19-9, a tumour-associated marker most often used in pancreatic and biliary disease assessment and monitoring, although benign conditions can also raise it.
Prostate Specific Antigen (Total)
Measures total PSA produced by prostate tissue, supporting assessment of prostate-related conditions when interpreted alongside age, symptoms, examination and other prostate investigations.
Lactate Dehydrogenase
Measures LDH, an enzyme released during tissue injury and increased cell turnover that can provide additional information but is highly non-specific.
Who May Benefit From the Male Tumour Markers Test?
This profile may be appropriate where several tumour-associated biomarkers have been specifically requested as part of a wider clinical assessment or monitoring plan.
Men undergoing investigation following an abnormal clinical finding - Tumour markers can provide supplementary information alongside examination, imaging and other investigations.
Men with previous abnormal PSA or other tumour-marker results - Repeat testing can help establish whether a marker is stable, rising or returning towards baseline.
People undergoing clinician-directed monitoring after a known cancer diagnosis - Selected tumour markers can be useful for follow-up where the relevant marker was informative for that particular cancer.
Men with prostate-related concerns - Total PSA can contribute to prostate assessment but should not be interpreted independently.
People with abnormal liver or pancreatic imaging under clinical review - AFP or CA 19-9 can sometimes provide complementary laboratory information.
People with a relevant personal medical history - Previous cancer or selected pre-existing conditions can make marker trends clinically useful.
People advised to undergo a multi-marker panel by a clinician - Several markers can be measured from one blood sample where there is an appropriate clinical reason.
Men wanting broader health assessment who understand the limitations of tumour markers - Results need careful interpretation because normal values do not exclude cancer and raised values do not establish it.
How to Prepare
Do not stop prescribed medication simply to alter tumour-marker results.
If PSA is being monitored over time, using similar pre-test conditions can make serial results easier to compare.
Tumour-marker values should be interpreted with clinical history rather than as an isolated cancer screen.
Symptoms and Reasons to Consider the Male Tumour Markers Test
Tumour markers do not correspond to a single symptom pattern, and symptoms should never be interpreted through tumour-marker results alone.
A previous abnormal PSA result - Total PSA can be repeated to assess the trend alongside appropriate prostate assessment.
Persistent urinary symptoms - Difficulty urinating, altered urinary flow or other prostate symptoms require clinical assessment and may prompt PSA testing.
Unexplained weight loss - Persistent unintentional weight loss warrants medical review and cannot be investigated adequately with tumour markers alone.
Persistent unexplained abdominal symptoms - Imaging and clinical evaluation are usually more important, with markers sometimes providing supplementary information.
Abnormal liver imaging or liver findings - AFP may be used alongside specialist liver investigation in appropriate circumstances.
A previous raised CEA or CA 19-9 result - Repeat measurement can be useful where a clinician is monitoring an established trend.
Known cancer under follow-up - Tumour-marker trends can sometimes contribute to treatment monitoring or surveillance.
An abnormal imaging or examination finding - Blood markers may be added as part of a broader diagnostic pathway.
This profile cannot diagnose cancer and cannot reliably rule cancer out.
Tumour markers can be raised by benign conditions and can remain normal in some people with cancer.
Persistent symptoms, a new lump, unexplained bleeding, significant unintentional weight loss, abnormal imaging or other concerning findings require appropriate clinical assessment regardless of tumour-marker results.
How to Book Your Male Tumour Markers Test
The Male Tumour Markers profile can be booked privately for laboratory measurement of five cancer-associated biomarkers.
Choose the Male Tumour Markers
Select the Male Tumour Markers profile online.
Select your sample collection option
Choose an in-clinic blood draw or professional home or hotel phlebotomy where suitable.
Attend your appointment
A trained healthcare professional collects the required venous blood sample and relevant prostate or medical information can be documented.
Laboratory analysis
Your sample undergoes measurement of Carcino Embryonic Antigen, Alpha Fetoprotein, Cancer Antigen 19-9, Prostate Specific Antigen (Total) and Lactate Dehydrogenase.
Receive your results securely
Your authorised results are delivered securely and should be interpreted alongside medical history, examination, imaging and previous results where appropriate.
When Will I Receive My Results?
The current live London Blood Tests page lists a turnaround of approximately 1 day after laboratory receipt for the Male Tumour Markers profile.
The five biomarkers undergo laboratory analysis, quality-control procedures and result authorisation.
Turnaround begins when the specimen reaches the laboratory rather than necessarily from the exact time of collection.
Where an unexpected result requires repeat analysis or further testing, the overall investigation can take longer.
Understanding Your Results
Each biomarker must be interpreted individually and in clinical context.
A raised marker does not automatically indicate cancer.
Likewise, normal tumour-marker results do not exclude cancer.
Carcino Embryonic Antigen can be raised in colorectal and other malignancies, but smoking, inflammation, liver disease and other non-malignant conditions can also affect it.
CEA trends are often more informative than one isolated result when it is being used for established cancer monitoring.
Alpha Fetoprotein can be raised with hepatocellular carcinoma and certain germ-cell tumours.
It can also increase in some non-malignant liver conditions.
Cancer Antigen 19-9 can rise in pancreatic and biliary malignancies but is not cancer-specific.
Bile-duct obstruction, pancreatitis and other benign conditions can produce elevated results.
Some people also do not produce CA 19-9 because of their Lewis antigen status.
Prostate Specific Antigen (Total) can rise with prostate cancer but also with benign prostate enlargement, inflammation, infection and recent prostate stimulation.
Age, symptoms and changes over time are important.
Lactate Dehydrogenase can rise with tissue damage or increased cell turnover from many different causes.
It is therefore especially non-specific.
Any abnormal result should be considered in relation to the reason for testing rather than interpreted as a standalone cancer result.
Why Book With London Blood Tests?
London Blood Tests provides private access to five tumour-associated blood markers within one focused male profile.
Measures 5 laboratory biomarkers - The profile combines CEA, AFP, CA 19-9, Total PSA and LDH.
Includes a prostate marker - Total PSA provides information relevant to prostate assessment when interpreted appropriately.
Includes gastrointestinal and hepatobiliary-associated markers - CEA, AFP and CA 19-9 can provide supplementary information in selected clinical settings.
Includes Lactate Dehydrogenase - LDH provides an additional marker of tissue injury and cell turnover.
Suitable for trend monitoring - Repeat results can sometimes be more informative than isolated measurements where a marker is already being followed.
Rapid laboratory turnaround - Results are currently expected approximately 1 day after laboratory receipt.
Professional blood collection - Clinic and suitable home or hotel phlebotomy appointments are available.
Clear pricing - The Male Tumour Markers profile costs £299.
Private Male Tumour Markers Blood Test in London
London Blood Tests provides private Male Tumour Markers testing for people requiring a focused panel of five cancer-associated laboratory markers.
The profile costs £299 and assesses 5 biomarkers.
Results are expected approximately 1 day after laboratory receipt.
The profile should not be used as a standalone cancer diagnosis or as reassurance that cancer is absent.
Abnormal results should be interpreted alongside symptoms, medical history, clinical assessment and imaging where appropriate.